Qt Vascular Ltd (QTVLF) 0.0960 $QTVLF
QT Vascular Ltd. - AngioScore Litigation Additional Updates
PR Newswire - Wed Jul 08, 2:10AM CDT
Further to the Company's announcement of 29 April 2015 and 2 July 2015, and media release of 4 May 2015, the Board of Directors of the Company ("Board"
would like to provide the following additional updates to shareholders of the Company in relation to the lawsuit filed by AngioScore, namely the State Law Claims and Patent Claim:
Federal Court in California Awards AngioScore $20 Million Plus Disgorgement in Breach of Fiduciary Duty Case
GlobeNewswire - Thu Jul 02, 7:00AM CDT
The Spectranetics Corporation (Nasdaq:SPNC) today announced that the U.S. District Court for the Northern District of California has ruled in favor of its wholly-owned subsidiary, AngioScore Inc., in a lawsuit filed by AngioScore seeking damages for breach of fiduciary duty against Eitan Konstantino, a former board member of AngioScore and founder of TriReme Medical, LLC, Quattro Vascular Pte Ltd. and QT Vascular Ltd. (SGX:5I0). The Court found that Konstantino breached his fiduciary duties to AngioScore, that TriReme and Quattro aided and abetted that breach, and that QT Vascular is liable for the acts of TriReme and Quattro. The Court awarded AngioScore $20.034 million against all defendants plus disgorgement from Konstantino of all benefits he accrued from his breach of fiduciary duties, including amounts he received for assigning his intellectual property rights to the Chocolate balloon, a royalty on past and future sales of the Chocolate balloon, and all of his shares and options in QT Vascular. Under the indemnification agreement between AngioScore and Konstantino, AngioScore will seek to recover attorney fees and costs previously advanced to Konstantino.
SPNC: 24.87 (+0.36)
Global Cardiac Prosthetic Devices (Prosthetic Heart Valves and Coronary Stents) Market 2015-2019 - Rise in Birth Prevalence of Congenital Heart Disease Worldwide
M2 - Wed Jun 24, 5:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/672rjb/global_cardiac) has announced the addition of the "Global Cardiac Prosthetic Devices Market 2015-2019" report to their offering. The global cardiac prosthetic market to grow at a CAGR of 8.41% over the period 2014-2019. Prosthetic devices are used to replace or support the function of a missing or infirm part in the body. Cardiac prosthetic devices such as stents and prosthetic heart valves are used to maintain the proper functionality of the heart. Stents are used to maintain the blood flow, which reduces due to blockage in the arteries, whereas prosthetic heart valves are being used by patient with heart valvular disease or dysfunctional heart valve. The use of low-profile coronary stents has the potential to simplify the delivery system and increase the number of suitable candidates for endovascular repair. This is mainly because of their accuracy in placement, ease of use, and effectiveness in navigational challenges that occur during repair. Aortic stents have a diameter of 18 to 22 Fr. There are new technically advanced stents that have an outer diameter of less than 16 Fr. These low-profile stents are smooth and soft, which enables accurate device deployment and fulfills the need for a smaller-diameter delivery system to treat patients with inadequate access to limb vessels. According to the report, congenital heart disease is defined as a defect in the structure of the heart and the great vessels that are present at the time of birth. Defects can exist in the form of obstruction in blood flow or the flow of blood in an abnormal pattern. According to the JACC, there are 1.35 million newborns with congenital heart disease every year worldwide. It is estimated that eight per 1,000 live births are affected by congenital heart disease. In addition, congenital heart disease is responsible for 4.2% of all neonatal deaths. Further, the report states that a rise in complications and the need for re-intervention with stents are hindering the growth of the market. Key vendors - Boston Scientific - Edwards Lifesciences - Medtronic - Sorin Group - St. Jude Medical Other prominent vendors - AorTech International - Abbott Vascular - Accellent - Admedes Schuessler - Alvimedica - Arbor Surgical - B. Braun Melsungen - Biosensors International - Biotronik - Boston Scientific - Bracco AMT - Colibri Heart Valve - Elixir Medical - eucatech - Eurocor - Hexacath - InspireMD - InSitu Technologies - iVascular - LEPU MEDICAL - Meril Life Sciences - Merit Medical - OrbusNeich - QT Vascular - Rontis - SCITECH - Shanghai MicroPort Scientific - STENTYS - Svelte Medical Systems - Symetis - Translumina For more information visit http://www.researchandmarkets.com/research/67...al_cardiac
BSX: 17.60 (+0.15), MDT: 74.37 (+1.28), STJ: 75.33 (+0.79), MDSY: 1.62 (-0.18), EW: 147.16 (+2.09)
QT Vascular Announces First Patients Enrolled In Clinical Study Of Chocolate Touch(TM) PTCA Coronary Drug-Coated Balloon
PR Newswire - Wed May 20, 6:14PM CDT
QT Vascular Ltd., together with its subsidiaries ("QT Vascular" or the "Group" , a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease, today announced it has enrolled the first 11 patients in its First-In-Human (FIH) study of its novel Chocolate Touch(TM) PTCA (Coronary Drug Coated Chocolate®) in the Dominican Republic.
QT Vascular Announces Acquisition of Novel Technology for Interventional Treatment
PR Newswire - Thu Oct 23, 10:05AM CDT
Catalist-listed QT Vascular Ltd. ("QT Vascular" or together with its subsidiaries, "the Group" , a developer and manufacturer of minimally invasive medical devices for the treatment of vascular diseases, is pleased to announce that the Group has acquired a novel technology platform called Java, and all associated intellectual property, which was developed independently in Israel.
First European Patients Enrolled in QT Vascular's ENDURE Trial
PR Newswire - Mon Sep 15, 12:00PM CDT
Catalist-listed QT Vascular Ltd. ("QT Vascular" or together with its subsidiaries, "the Group" , a developer and manufacturer of minimally invasive medical devices for the treatment of vascular diseases, is pleased to announce that the Group has enrolled the first European patients in the ENDURE Trial in Germany. Multiple patients have already been enrolled in this study with Dr. Andrew Holden, at Auckland City Hospital, in Auckland, New Zealand.
QT Vascular Ltd. - AngioScore Litigation Additional Updates
PR Newswire - Wed Jul 08, 2:10AM CDT
Further to the Company's announcement of 29 April 2015 and 2 July 2015, and media release of 4 May 2015, the Board of Directors of the Company ("Board"
would like to provide the following additional updates to shareholders of the Company in relation to the lawsuit filed by AngioScore, namely the State Law Claims and Patent Claim: Federal Court in California Awards AngioScore $20 Million Plus Disgorgement in Breach of Fiduciary Duty Case
GlobeNewswire - Thu Jul 02, 7:00AM CDT
The Spectranetics Corporation (Nasdaq:SPNC) today announced that the U.S. District Court for the Northern District of California has ruled in favor of its wholly-owned subsidiary, AngioScore Inc., in a lawsuit filed by AngioScore seeking damages for breach of fiduciary duty against Eitan Konstantino, a former board member of AngioScore and founder of TriReme Medical, LLC, Quattro Vascular Pte Ltd. and QT Vascular Ltd. (SGX:5I0). The Court found that Konstantino breached his fiduciary duties to AngioScore, that TriReme and Quattro aided and abetted that breach, and that QT Vascular is liable for the acts of TriReme and Quattro. The Court awarded AngioScore $20.034 million against all defendants plus disgorgement from Konstantino of all benefits he accrued from his breach of fiduciary duties, including amounts he received for assigning his intellectual property rights to the Chocolate balloon, a royalty on past and future sales of the Chocolate balloon, and all of his shares and options in QT Vascular. Under the indemnification agreement between AngioScore and Konstantino, AngioScore will seek to recover attorney fees and costs previously advanced to Konstantino.
SPNC: 24.87 (+0.36)
Global Cardiac Prosthetic Devices (Prosthetic Heart Valves and Coronary Stents) Market 2015-2019 - Rise in Birth Prevalence of Congenital Heart Disease Worldwide
M2 - Wed Jun 24, 5:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/672rjb/global_cardiac) has announced the addition of the "Global Cardiac Prosthetic Devices Market 2015-2019" report to their offering. The global cardiac prosthetic market to grow at a CAGR of 8.41% over the period 2014-2019. Prosthetic devices are used to replace or support the function of a missing or infirm part in the body. Cardiac prosthetic devices such as stents and prosthetic heart valves are used to maintain the proper functionality of the heart. Stents are used to maintain the blood flow, which reduces due to blockage in the arteries, whereas prosthetic heart valves are being used by patient with heart valvular disease or dysfunctional heart valve. The use of low-profile coronary stents has the potential to simplify the delivery system and increase the number of suitable candidates for endovascular repair. This is mainly because of their accuracy in placement, ease of use, and effectiveness in navigational challenges that occur during repair. Aortic stents have a diameter of 18 to 22 Fr. There are new technically advanced stents that have an outer diameter of less than 16 Fr. These low-profile stents are smooth and soft, which enables accurate device deployment and fulfills the need for a smaller-diameter delivery system to treat patients with inadequate access to limb vessels. According to the report, congenital heart disease is defined as a defect in the structure of the heart and the great vessels that are present at the time of birth. Defects can exist in the form of obstruction in blood flow or the flow of blood in an abnormal pattern. According to the JACC, there are 1.35 million newborns with congenital heart disease every year worldwide. It is estimated that eight per 1,000 live births are affected by congenital heart disease. In addition, congenital heart disease is responsible for 4.2% of all neonatal deaths. Further, the report states that a rise in complications and the need for re-intervention with stents are hindering the growth of the market. Key vendors - Boston Scientific - Edwards Lifesciences - Medtronic - Sorin Group - St. Jude Medical Other prominent vendors - AorTech International - Abbott Vascular - Accellent - Admedes Schuessler - Alvimedica - Arbor Surgical - B. Braun Melsungen - Biosensors International - Biotronik - Boston Scientific - Bracco AMT - Colibri Heart Valve - Elixir Medical - eucatech - Eurocor - Hexacath - InspireMD - InSitu Technologies - iVascular - LEPU MEDICAL - Meril Life Sciences - Merit Medical - OrbusNeich - QT Vascular - Rontis - SCITECH - Shanghai MicroPort Scientific - STENTYS - Svelte Medical Systems - Symetis - Translumina For more information visit http://www.researchandmarkets.com/research/67...al_cardiac
BSX: 17.60 (+0.15), MDT: 74.37 (+1.28), STJ: 75.33 (+0.79), MDSY: 1.62 (-0.18), EW: 147.16 (+2.09)
QT Vascular Announces First Patients Enrolled In Clinical Study Of Chocolate Touch(TM) PTCA Coronary Drug-Coated Balloon
PR Newswire - Wed May 20, 6:14PM CDT
QT Vascular Ltd., together with its subsidiaries ("QT Vascular" or the "Group"
, a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease, today announced it has enrolled the first 11 patients in its First-In-Human (FIH) study of its novel Chocolate Touch(TM) PTCA (Coronary Drug Coated Chocolate®) in the Dominican Republic. QT Vascular Announces Acquisition of Novel Technology for Interventional Treatment
PR Newswire - Thu Oct 23, 10:05AM CDT
Catalist-listed QT Vascular Ltd. ("QT Vascular" or together with its subsidiaries, "the Group"
, a developer and manufacturer of minimally invasive medical devices for the treatment of vascular diseases, is pleased to announce that the Group has acquired a novel technology platform called Java, and all associated intellectual property, which was developed independently in Israel. First European Patients Enrolled in QT Vascular's ENDURE Trial
PR Newswire - Mon Sep 15, 12:00PM CDT
Catalist-listed QT Vascular Ltd. ("QT Vascular" or together with its subsidiaries, "the Group"
, a developer and manufacturer of minimally invasive medical devices for the treatment of vascular diseases, is pleased to announce that the Group has enrolled the first European patients in the ENDURE Trial in Germany. Multiple patients have already been enrolled in this study with Dr. Andrew Holden, at Auckland City Hospital, in Auckland, New Zealand. 
